| Name | Title | Contact Details |
|---|
Shasqi develops cancer treatment intended to use bio-orthogonal chemistry for localized drug delivery.
Our vision is to become the leading innovative global life-sciences company that unlocks the potential of T-cell biology and combines it with the power of T-cell engineering excellence to provide cures for patients. Through our model of seamless and rapid integration of research, translational medicine, manufacturing science, clinical development and customer-centric approaches, we will design and deliver enhanced state-of-the-art solutions for patients in a host of disease areas using Chimeric Antigen Receptors (CARs), Gene edited T-Cells, T regulatory cells (Treg), and engineered T Cell Receptors (TCRs)
Pioneering the next generation of non-viral gene therapy - by tackling more diseases, more precisely and in a more personalized way.